Royalty Pharma plc
HealthcareNASDAQ:RPRX · NASDAQ Global Select
-$0.14 today
Vol 1.57M · Avg 3.65M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.3B -0.5% | $1.3B -21.7% | $1.7B +639.0% | $230.1M -81.5% | $1.2B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.9M | $0 | $0 -100.0% | $5.7M -75.3% | $23.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $289.9M +12267.5% | $2.3M -0.6% | $2.4M +8.6% | $2.2M -11.2% | $2.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$17.2M -132.1% | $53.4M +891.9% | $5.4M -83.5% | $32.7M +300.1% | -$16.3M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$2.4M +48.1% | -$4.6M -199.2% | -$1.5M +67.9% | -$4.7M +83.7% | -$29.1M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$13.9M -508.2% | -$2.3M -136.7% | $6.2M +172.8% | $2.3M +149.8% | -$4.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$863.0K -101.4% | $60.2M +8929.1% | $667.0K -98.1% | $35.1M +101.8% | $17.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $889.0M -35.7% | $1.4B +8.0% | $1.3B -31.7% | $1.9B +144.2% | $767.2M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $2.5B -10.1% | $2.8B -7.3% | $3.0B +39.4% | $2.1B +6.3% | $2.0B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$74.4M -579.3% | -$11.0M +12.7% | -$12.5M -26.7% | -$9.9M +71.6% | -$34.9M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.9B +29.4% | -$2.7B -29.3% | -$2.1B +17.5% | -$2.6B +28.6% | -$3.6B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $566.5M +378.6% | $118.4M +358.2% | $25.8M -98.3% | $1.5B -13.0% | $1.8B | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$175.1M -255.0% | -$49.3M -267.5% | $29.4M | $0 +100.0% | -$18.1M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$1.6B +39.7% | -$2.7B -29.2% | -$2.1B -101.4% | -$1.0B +45.0% | -$1.9B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $954.5M -35.1% | $1.5B +247.1% | -$1.0B | $0 -100.0% | $1.3B | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$1.2B -434.5% | -$229.7M +24.6% | -$304.8M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$378.3M -0.5% | -$376.5M -5.1% | -$358.3M -7.5% | -$333.3M -16.9% | -$285.2M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$534.8M -6.1% | -$504.0M -3.8% | -$485.7M +20.6% | -$611.5M -1.5% | -$602.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$1.2B -428.4% | $361.1M +116.8% | -$2.1B -127.4% | -$944.9M -345.3% | $385.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$310.3M -168.7% | $452.0M +136.6% | -$1.2B -827.0% | $169.7M -68.1% | $532.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $2.5B -10.1% | $2.8B -7.3% | $3.0B +39.4% | $2.1B +6.3% | $2.0B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
United Therapeutics Corporation
NASDAQ:UTHR
$23.00B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.79B
Incyte Corporation
NASDAQ:INCY
$21.78B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.37B
Tenet Healthcare Corporation
NYSE:THC
$15.26B
Exelixis, Inc.
NASDAQ:EXEL
$13.39B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.59B
SEC Filings
Recent regulatory filings
No filings found.
Does RPRX generate free cash flow?
Royalty Pharma plc (RPRX) generated $2.49B of free cash flow in fiscal 2025.
How much operating cash flow does RPRX produce?
Operating cash flow was $2.49B, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.